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Abstract
Infection with human papillomavirus (HPV) is a major risk factor for development of anal squamous cell carcinoma.
Despite over 100 genotypes of the virus, HPV 16 and 18 are considered pathogenic as they are seen in the major-
ity of cervical and anal cancers. We have employed a custom microarray to examine DNA for several HPV geno-
types. We aimed to determine the accuracy of our microarray in anal cancer DNA for HPV genotypes compared to
the DNA sequencing gold standard.
Methods: We utilized a sensitive microarray platform to classify 37 types of mucosal HPVs including 14 known
high-risk and 23 low-risk types based on cervical cancer data. We utilized DNA from pathologically confirmed cases
of anal squamous cell carcinoma. All samples underwent microarray HPV genotyping and PCR analysis.
Results: HPV was detected in 18/20 (90%) anal cancers. HPV genotypes 16 and 18 were present in the majority of
specimens, with HPV 16 being the most common. Eighty percent of anal cancers had at least two HPV types. Ten
percent of cases (2/20) tested negative using our microarray; DNA sequencing confirmed the lack of presence of
HPV DNA in these samples.
Conclusions: Microarray technology is an accurate way to screen for various genotypes of HPV in anal cancer, with
100% correlation with genomic DNA detection of HPV. The majority of anal cancers in our study associated with
pathogenic HPV 16 and/or 18. Other HPV genotypes are present simultaneously with HPV 16 and 18, and might
contribute to its pathogenesis.
Introduction
Squamous cell cancer of the anus (anal cancer) is
increasing in frequency in the general population in the
United States, Europe and South America [1]. There
were an estimated 4000 new cases in 2003 in the United
States [2], and that number was estimated to be 5290
for 2009 [3]. Despite the increasing numbers of patients
with anal cancer, little has changed in the paradigm for
the treatment and outcomes from this disease. Anal
cancer was initially thought to develop from conditions
of chronic inflammation such as perianal Crohn’sd i s -
ease; however genital viral infection with HPV with or
without a concomitant immunocompromised condition
has been shown to be the major risk factor for the
development of anal dysplasia, a precursor lesion to
squamous cell cancer of the anus. There are likely over
100 genotypes of the virus, however types HPV 16 and
18 are considered “high risk” as they are seen in the
majority of cervical and anal cancer specimens [4]. Little
data exists confirming the presence of these types or
other genotypes in squamous cell cancer of the anus.
With cervical cancers, line probe assays and reverse line
blot (RLB) assays have been utilized, with RLB assays
better at detecting multiple HPV infections, but none of
these tests are universally agreed upon for detection
purposes [5]. To date, most studies in anal cancer have
used DNA hybridization, PCR techniques and DNA
sequencing to identify and confirm the presence or
absence of HPV 16, 18 [6,7]. While most anogenital
cancers are believed to be associated with HPV 16 and
18, the additive presence of other “high risk” types is
unknown. We have developed and utilized a microarray
platform to examine DNA for HPV genotyping in anal
carcinomas. In this study, we aimed to determine the
accuracy of our microarray technology to examine anal
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techniques as the gold standard.
Methods
DNA Extraction
Under IRB approval, DNA was extracted from pathologi-
cally confirmed cases of anal cancer from two local hos-
pitals: UC San Diego Medical Center and the Veteran’s
Administration Hospital in San Diego, California. A total
of 20 patient samples were collected from these two can-
cer registries for use in this study. The average age of the
patients was 51.5 (range 39-77) and 85% of patients were
males. Staging was performed by computed tomography,
and listed by AJCC classification in Table 1. All samples
were taken before treatment with chemoradiation; in
some cases the lesions were treated with surgery alone.
Of the 20 cases, 45% (N = 9) were known to be HIV posi-
tive. All samples were histologically confirmed by a single
pathologist prior to experiments (KM).
DNA tissue was extracted after manual or laser cap-
ture microscopy microdissection of pathologist-marked
cancer areas from histological-confirmed slides of squa-
mous cell cancer of the anus. This tissue was then
deparaffinized in xylene, purified with absolute alcohol,
and centrifuged at 15,000 rpm. The pellets were dried in
a DNA SpeedVac (Eppendorf Vacufuge Concentrator),
re-suspended in 100 μl Tris EDTA buffer, and incubated
with 200 ug/ml proteinase K (Sigma Cat#P2308) at 55°C
for 3 hours. The genomic DNA was purified with phe-
nol/chloroform/isoamyl alcohol (25:24:1, Sigma cat,
P-3803) and washed with alcohol. The resulting solute
was re-suspended in TE buffer. Purified DNA was then
subject to amplification for microarray analysis.
DNA was also extracted from cell lines in which the
HPV status was known. SiHa (HPV16, 1-2 copies/cell),
HeLa (HPV-18, 10-50 copies/cell), CaSki (HPV-16, 60-
600/cell) and ME180 (HPV-68) were obtained from
ATCC and grown in their ATCC-recommended media
at 37°C in 5% CO2.
HPV DNA Amplification
We used a modification of the standard GP5+/GP6+
protocol [8]. Modified primers, termed B-GP5+ and B-
GP6+, containing a 5’ extension of 17mer primer B
sequence (GTTTCCCAGTCACGATC) to the original
GP5+ and GP6+ primers, were used for the initial PCR
amplification from samples. The initial PCR product
was further amplified and labeled with amino-allyl
dUTP by using the B primer for the 2
nd PCR. Subse-
quently, the labeled product was then coupled with Cy-
3 NHS ester for array hybridization. This approach
demonstrates the usefulness of this method for detection
of the amplified viral amplicons when multiple viral
types or genotypes might be present [9,10].
HPV Genotyping Chip
A microarray platform was built to type 37 types of
mucosal HPVs (see Figure 1) that include 14 presumed
high-risk types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, 66 and 68; and 23 presumed low-risk types: 6,
11, 26, 34, 40, 42, 43, 44, 53, 54, 55, 57, 61, 70, 71, 72,
73, 81, 82/MM4, 82/IS39, 83, 84 and CP6108. The
probes were all 30-mer in length including forward
and reverse orientations and were located in a 150 bp
L1 fragment that is bordered by primers GP5+ and
GP6+ as previously described [8]. Each HPV type is
represented by a pair of probes (for example, two
HPV16 spots indicated in Figure 1), which correspond
to one set of oligonucleotide sequences complementary
to each other. The location of each probe is identified
by the scanner software using a premade grid file with-
out special pattern arrangement. Prior to printing,
every HPV-specific oligonucleotide probe was mixed
with a Spike-70 oligonucleotide probe at the ratio of
50:1 for a given spot on the glass slide [11]. Probe-70
is labeled with Cy-5 dye (red in Figure 1) and is the
reverse complement sequence to Spike-70. Probe-70 is
mixed with HPV DNA (labeled with Cy3, green in
Figure 1) amplified from samples. Since all spots con-
tain probes for Spike-70, all spots show up in the red
channel when scanned. However, if the spot contains
probes for an HPV type in the sample, then the green
Table 1 HPV infection and genotype among our cohort
of human anal cancers
CASE HPV STATUS BY
PCR
HPV GENOTYPE BY
MICROARRAY
AJCC Stage*
1 Positive 11, 16, 43 T2N2M0 = 3B
2 Positive 18 T3N1M0 = 3A
3 Positive 16 T1N0M0 = 1
4 Positive 16, 18 T2N0M0 = 1
5 Positive 16,18 T3N0M0 = 2
6 Positive 16, 18 T2N1M0 = 3A
7 Positive 16, 18 T3N0M0 = 2
8 Positive 18, 33 T2N0M0 = 1
9 Positive 16, 18 T2N0M0 = 1
10 Positive 16, 18 T1N0M0 = 1
11 Positive 6, 16 T2N1M0 = 3
12 Positive 16, 33 T2N0M0 = 1
13 Positive 11, 16 T3N1M1 = 4
14 Positive 16, 18 T3N0M0 = 2
15 Positive 16, 18 T2N1M1 = 4
16 Positive 16, 18 T2N0M0 = 2
17 Positive 16, 18 T1N0M0 = 1
18 Positive 16, 18 T2N2M0 = 3B
19 Negative Negative T2N0M0 = 1
20 Negative Negative T3N0M0 = 2
* Reference American Joint Committee on Cancer: AJCC Cancer Staging
Manual. 6th ed. New York, NY: Springer, 2002, pp 125-130.
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signal from the Spike-70:Probe-70 hybridization to
yield a yellowish spot dependent on the ratio of green
to red. Each probe was spotted four times on the chip
(Figure 1). The microarray fabrication procedure has
been described previously [9,11].
Results
HPV genotyping and detection by microarray
We used SiHa (a known HPV 16 positive cervical cancer
cell line) genomic DNA for analyzing the limit of detec-
tion to mimic the complexity of HPV16 in the presence
of human genomic DNA. SiHa cells contain a single
HPV-16 integrated into chromosome 13q [12]. The
human genome is about 3.3 billions base pairs, therefore,
each ng of genomic DNA contains about 3 × 10
5 mole-
cules of human genome. A total of 100 ng SiHa genomic
DNA was sequentially diluted in water, amplified, labeled
and hybridized to the HPV typing chip. SiHa (1-2 inte-
grated HPV16/cell) genomic DNA was applied for titra-
tion experiment. The sensitivity with the HPVGP56 array
is about 1-2 copies of HPV16 in the background of com-
plex human genomic DNA. (The detection limit was
about 6.4 pg of genomic DNA, which is equivalent to 2
copies of haploid human genome, 3.6 pg/haploid gen-
ome). We were able to unambiguously identify features
r e p r e s e n t i n gH P V 1 6w h e no n l y1o r2c o p i e so fg e n o m e
were present in the sample.
To test the specificity of the array, 100 ng each of
genomic DNA from SiHa (HPV16, 1-2 copies/cell),
HeLa (HPV-18, 10-50 copies/cell), Caski (HPV-16, 60-
600/cell) and ME180 (HPV-68) were used for amplifica-
tion, labeling and chip hybridization [12,13]. The micro-
array results accurately identified each of the respective
HPV types from each cell line. One of the array typing
results from clinical samples is shown in Figure 1, with
this particular tumor sample was positive for HPV 16
and HPV 33.
HPV typing of anal cancer
After extracting the DNA for anal cancer specimens and
hybridizing to the microarray, HPV was detected in 18/
20 (90%) cases. All the samples were separately subject
to PCR amplification and DNA sequencing analysis to
confirm the presence or absence of HPV DNA in the
cancer specimens and test the accuracy of the microar-
ray platform. Genomic DNA from the anal cancer sam-
ples was used for GP5+/6+ primer PCR [14], a
conserved region within HPV, both positive controls for
HPV cancer cell lines (Hela, CaSki, SiHa) and negative
controls were used to validate results (Figure 2).
DNA sequencing confirmed a 100% correlation
between the HPV microarray and DNA sequencing ana-
lysis (Figure 2 and Table 1). Of the two cases that had
no HPV detected by microarray, lack of HPV DNA was
further confirmed by DNA sequencing analysis, suggest-
ing 100% specificity (Table 1). Of the cases that were
positive for HPV, 100% were initially detected by HPV
microarray, with confirmation via DNA amplification
and DNA sequencing.
We identified that anal cancers often contain more
than one HPV genotype. Types 16 and 18 were present
in the majority of our specimens, accounting for
approximately 80% of the HPV detected, with HPV 16
being the most common (Table 1). Only 10% of cases
demonstrated a single genotype infection with either
HPV 16 or 18 alone, whereas more than 50% of our
patients were infected with both HPV 16 and 18 and/or
another high risk type such as HPV 33 (Table 1). Over-
all, approximately 80% of the anal cancers demonstrated
more than one HPV genotype. All extracted tissue spe-
cimens underwent DNA sequencing to confirm the
Figure 1 DNA HPV Microarray of Human Anal Cancer. As explained in the Methods section, the yellow-green spots on the microarray
indicate positive hybridization for HPV. This human anal cancer sample is positive for HPV-16 and HPV-33. Each HPV genotype is represented by
two single-stranded oligonucleotide probes (i.e. forward and reverse complementary orientations).
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between the AJCC stage and HPV genotype.
Discussion
A major risk factor for squamous cell cancer of the anus
is HPV infection. HPV’s E6 and E7 oncoproteins can
inactivate crucial cell cycle regulators such as p53 and
pRb, telomere maintenance, apoptosis and induce chro-
mosome instability [2,6]. Anal cancer is commonly asso-
ciated with HPV genotypes 16 and 18. Although as
many as 100 different genotypes may exist, there has
been no previous evaluation of multiple types that could
be present in anal cancer. We developed a relatively
rapid way to evaluate multiple HPV genotypes at once
within anal cancer and studied whether this correlated
with the gold standard of individual HPV DNA sequen-
cing. We found 100% agreement between our microar-
ray method when compared to DNA sequencing.
Utilizing microarray technology to subtype the presence
of HPV in squamous cell cancer of the anus, we
detected a high rate of HPV infection within anal can-
cer, with 90% in our cohort of patients. This is compar-
able to previous reports demonstrating HPV infection
rates from 75-80% [15,16].
The frequency of HPV detection in anal cancer under-
scores its dominance as a risk factor for this disease. We
detected HPV types 16 and 18 in 70% of anal cancers,
consistent with these genotypes associated with anal
cancer pathogenesis. A recent meta-analysis suggests
that HPV16 is found more frequently (75%) and HPV18
less frequently (10%) in anal carcinomas than in cervical
carcinomas [17]. However, only 10% of our cohort of
anal cancers had HPV type 16 or 18 alone. Indeed, HPV
types 16 and 18 together infected more than 50% of
anal cancers, which may or may not have implications
in its pathogenesis. Furthermore, approximately 80% of
anal cancers demonstrated more than one HPV geno-
type, including some infected with another high-risk
type such as HPV 33. The implication of this informa-
tion is unknown but the presence of multiple types may
affect disease progression, immunity and treatment
response. In the era of vaccines, the information about
multiple HPV genotype infections may become increas-
ingly important.
The analysis of HPV infection can be hindered by the
lack of consistency in collection and detection methods,
this is in part due to sample adequacy [18]. The micro-
array technology used in this study detected the pre-
sence of HPV in anal cancer DNA that was extracted
from formalin-fixed tissue taken from biopsy specimens.
This suggests that this method can be quite effective
with only a minimal sized sample and can detect multi-
ple HPV genotypes simultaneously. Previous studies
have demonstrated the presence of HPV genotypes in
anal cancer through PCR-based genotyping and com-
mercially available gene chip analysis, however this can
be expensive and time consuming for use in the clinical
setting [19-21]. We believe that if uniformly applied in
pathological laboratories, a microarray approach would
be less expensive plus have the added benefit of detect-
ing multiple genotypes of HPV. The application of a
microarray platform for HPV typing could have signifi-
cant implications for the prevention of HPV-related dis-
ease. The ability to identify and risk stratify those
patients with HPV 16 and HPV 18 and possibly other
genotypes may in the future, provide an opportunity for
surveillance and early intervention. It is not yet clear if
there is a genotype-stage correlation.
Figure 2 GP5+/GP6+ PCR for HPV. Human anal squamous genomic DNA samples were tested for the presence of HPV DNA. Hela, CaSki, and
SiHa cells are all HPV positive cervical cancer controls. The “+” indicates positive samples, and the “-” indicates negative samples for HPV
amplification in the upper panel. The lower panel demonstrates actin as an amplification control of the same samples. The leftmost lane
contains a 100 base pair ladder marker. NEG demarcates a negative control without sample DNA.
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accurate way to screen for the various genotypes of
HPV in anal cancer simultaneously, with a 100% corre-
lation with genomic DNA detection of HPV in this
cohort. The majority of anal cancers in our study is
associated with HPV subtypes 16 and/or 18 and like
cervical cancer, are the major genotypes associated with
the cancer. Other HPV genotypes can be present in anal
cancer and often occur simultaneously with genotypes
16 and 18, and might contribute to the progression of
pathogenesis.
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